Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Abbott and Eisai file for approval of second indication of adalimumab in Japan

Sep. 26, 2007

Recent Eisai patent reports new antipruritic agents for atopic dermatitis

Sep. 25, 2007

Bristol-Myers begins phase II trial of p38 kinase inhibitor BMS-582949 for psoriasis

Sep. 20, 2007

Innocoll and TGR BioSciences to collaborate on CollaRx delivered TGR-265

Sep. 18, 2007

Positive results for Renovo's phase II trial of Juvista for treatment of wounds and scars

Sep. 14, 2007

Positive results for Moberg Derma's phase II trial of K-301 for seborrheic dermatitis

Sep. 13, 2007

Basilea submits MAA for oral alitretinoin for chronic hand eczema in Europe

Sep. 13, 2007

Update on Welichem's phase I trials of WBI-1001 for psoriasis

Sep. 13, 2007

Natural products in dermatology

Sep. 13, 2007

Antiinflammatory effects of the GABA-B agonist baclofen shown in mice

Sep. 12, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.